YMRC
KRYS icon

Yorktown Management & Research Company’s Krystal Biotech KRYS Stock Holding History

Yorktown Management & Research Company’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$743K Hold
2,000
– – 0.46% 67
2026
Q1 		$517K Hold
2,000
– – 0.43% 79
2025
Q4 		$493K Hold
2,000
– – 0.39% 92
2025
Q3 		$353K Buy
+2,000
New +$299K 0.28% 145

Other funds holding KRYS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Yorktown Management & Research Company's KRYS Position: Q2 2026 in Review

Yorktown Management & Research Company held its Krystal Biotech (KRYS) position steady in Q2 2026 at 2,000 shares worth $743K. The position accounts for 0.46% of the portfolio, ranked #67.

Yorktown Management & Research Company first reported a position in KRYS in Q3 2025 and has held it in 4 quarters since. 207 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Yorktown Management & Research Company held 2,000 shares of Krystal Biotech worth $743K as of Q2 2026.
  • Yorktown Management & Research Company left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up 0.46% of Yorktown Management & Research Company's portfolio in Q2 2026, its #67 holding.
  • Yorktown Management & Research Company first reported a position in Krystal Biotech in Q3 2025 and has held it in 4 quarters since.
  • 207 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.